<DOC>
	<DOC>NCT00444951</DOC>
	<brief_summary>This study will be conducted among adolescents in Saudi Arabia who previously received one dose of A, C, Y, W 135 and at least one dose of A, C meningococcal polysaccharide vaccine. This study will evaluate the booster administration of Menactra® (Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine) compared with Mencevax® (Meningococcal A, C, Y, and W 135 Polysaccharide vaccine)in terms of their serum bactericidal antibody responses.</brief_summary>
	<brief_title>Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy, as determined by medical history and physical examination. Aged between 16 to 19 years on the day of inclusion (from 16th birthday to 1 day before 20th birthday inclusive). For the Menactra® and Mencevax® groups, one dose of quadrivalent (A, C, Y, W 135) and at least one dose of bivalent (A, C) meningococcal polysaccharide vaccine with no meningococcal vaccine received less than 2 years prior to enrollment. For the Control group, no previous history of any meningococcal vaccination. Informed consent form signed by the parent(s) or other legal representative for subject under 18 years and signed by subject him/herself if subject above 18 years old Able to provide a vaccination log or has available vaccination record in the Health Center Able to attend all scheduled visits and to comply with all trial procedures Serious chronic disease (i.e., cardiac, renal, neurologic, metabolic, rheumatologic, psychiatric, etc.) Known or suspected impairment of immunologic function. Acute medical illness with or without fever within the last 72 hours or an oral temperature ≥ 37.5°C at the time of inclusion. Administration of immune globulin or other blood products within the last three months, injected or oral corticosteroids or other immunomodulatory therapy within six weeks of the study vaccine. Individuals on a tapering dose schedule of oral steroids lasting &lt; 7 days may be included in the trial provided that they have not received more than one course within the last two weeks prior to enrollment. Oral or injected antibiotic therapy within the 72 hours prior to vaccination Received any vaccine in the 14day period prior to study vaccination, or scheduled to receive any vaccination during the 14day period after study vaccination. Previous history of documented invasive meningococcal disease. Systemic hypersensitivity to any of the vaccines components or history of a lifethreatening reaction to the trial vaccines or a vaccine containing the same substances Participation in another clinical trial in the 4 weeks preceding the trial vaccination Planned participation in another clinical trial during the present trial period Any condition, which, in the opinion of the investigator, would pose a health risk to the subject, or interfere with the evaluation of the vaccine. Personal or family history of Guillain Barré syndrome. For female, known or suspected to be pregnant at the time of inclusion</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>N meningitidis</keyword>
</DOC>